Evidence map›Paper›PMID 39871246›Full record

ArticleCancer cell international2025

DLAT is involved in ovarian cancer progression by modulating lipid metabolism through the JAK2/STAT5A/SREBP1 signaling pathway.

Hui Wang, Shen Luo, Yue Yin, Yang Liu, Xiaomei Sun, Ling Qiu, Xin Wu

Abstract read
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui Wang *Department of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China.
Shen Luo *Department of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China.
Yue Yin *Department of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China.
Yang LiuDepartment of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China.
Xiaomei SunDepartment of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China.
Ling QiuDepartment of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China. QiuLingpang@163.com.
Xin WuDepartment of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China. wuxin_fc@fudan.edu.cn.

Funding

Public Welfare Project "JiShiQiYi" of Beijing Health Alliance Charitable Foundation KM-JSQY-002"ZaiDing-Le" Foundation from Beijing Kanghua Foundation for the Development of Traditional Chinese and Western Medicine KH-2020- LJJ-008
6 · The paper itself

Abstract

backgroundOvarian cancer (OC) remains a lethal gynecological malignancy with an alarming mortality rate, primarily attributed to delayed diagnosis and a lack of effective treatment modalities. Accumulated evidence highlights the pivotal role of reprogrammed lipid metabolism in fueling OC progression, however, the intricate underlying molecular mechanisms are not fully elucidated.

methodsDLAT expression was assessed in OC tissues and cell lines by immunohistochemistry, western blot and qRT-PCR analysis. The effects of DLAT silencing on changes in lipid metabolism, cell viability, migration, and invasion were examined in SKOV3 and OVCAR3 cells using CCK-8, colony formation, Transwell migration and invasion, and wound-healing assays. GSEA analysis was used to examine the relationship between DLAT and lipid metabolism-related enzymes. Rescue experiments in which SREBP1 was overexpressed in DLAT-silenced cells were carried out. Western blot analysis was performed to determine whether the JAK2/STAT5 signaling pathway was involved in DLAT-regulated SREBP1 expression. Commercially available triglyceride and cholesterol detection kits, as well as Nile Red and Oil red O staining were used to measure lipid metabolism. A subcutaneous tumor model was established in BALB/c mice to confirm the role of the DLAT/SREBP1 axis in OC growth and metastasis in vivo.

resultsDLAT expression was significantly upregulated in OC patient tissue and associated with poor prognosis. Silencing DLAT reduced lipid content and impaired OC cell proliferation, migration, and invasion. DLAT upregulated SREBP1 expression via the JAK2/STAT5 signaling pathway, enhancing expression of fatty acid synthesis enzymes and altering lipid metabolism. SREBP1 was essential for DLAT-dependent OC cell growth and metastasis both in vitro and in vivo.

conclusionThis study uncovers a novel DLAT/JAK2/STAT5/SREBP1 axis that reprograms lipid metabolism in OC, providing insights into metabolic vulnerabilities and potential therapeutic targets for OC treatment.

Indexed as

DLATJAK2/STAT5 signalingLipid metabolismOvarian cancerSREBP1

Identifiers

PMID39871246
PMCPMC11773875

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.